Fertility and Sterility Publishes Largest Outcomes Research to Date on Cicero Diagnostic’s BCL6 Protein Test for Unexplained Infertility

HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)-- #asrm--Cicero Diagnostics, Inc., the provider of the ReceptivaDx test, today announced that outcomes data from research that followed the progress of 189 IVF patients over a two-year period at seven major fertility centers across the country was published in Fertility and Sterility, the official journal of the American Society of Reproductive Medicine. Cicero Diagnostics hosted the “Shared Experience Program” that collected the data. The objective of the rese

Click to view original post